Selective serotonin reuptake inhibitors can adversely affect platelet function and impair hemostasis.
Various bleeding complications have been reported in persons taking selective serotonin reuptake inhibitors.
These complications included an increased risk of gastrointestinal (GI) hemorrhage.
Dr Wessinger and colleagues from the USA evaluated selective serotonin reuptake inhibitors use in patients hospitalized with GI hemorrhage vs controls.
The investigative team conducted a retrospective, multicenter case-control study.
The team determined use of selective serotonin reuptake inhibitors, and non-steroidal anti-inflammatory drugs.
| Selective serotonin reuptake inhibitor use was 19% in cases vs 14% in controls|
|Alimentary Pharmacology & Therapeutics|
The drugs included aspirin, clopidogrel, coumadin and enoxaparin.
Exclusion criteria included liver disease, portal hypertension or bleeding diathesis.
The investigators compared a total of 579 patients admitted with GI hemorrhage with 1000 age- and sex-matched controls.
Selective serotonin reuptake inhibitors use was 19% in cases and 14% in controls.
The investigative team found that non-steroidal anti-inflammatory drugs were used by 7% of cases and 4% of controls.
Selective serotonin reuptake inhibitors use was more strongly associated with lower rather than upper gastrointestinal hemorrhage.
The team observed significant interactions for selective serotonin reuptake inhibitors use with non-steroidal anti-inflammatory drugs and aspirin.
Dr Wessinger's team concludes, “Patients admitted with gastrointestinal hemorrhage were more likely to be taking selective serotonin reuptake inhibitors than controls.”
“This association exists for lower as well as upper gastrointestinal hemorrhage.”
“Physicians should be aware of this risk particularly in patients already using medications that increase gastrointestinal hemorrhage risk.”